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Abstract Apoptotic proteases cleave and inactivate survival
signaling molecules such as Akt/PKB, phospholipase C (PLC)-
Q1, and Bcl-2. We have found that treatment of A431 cells with
tumor necrosis factor-K in the presence of cycloheximide resulted
in the cleavage of epidermal growth factor receptor (EGFR) as
well as the activation of caspase-3. Among various caspases,
caspase-1, caspase-3 and caspase-7 were most potent in the
cleavage of EGFR in vitro. Proteolytic cleavage of EGFR was
inhibited by both YVAD-cmk and DEVD-fmk in vitro. We also
investigated the effect of caspase-dependent cleavage of EGFR
upon the mediation of signals to downstream signaling molecules
such as PLC-Q1. Cleavage of EGFR by caspase-3 significantly
impaired the tyrosine phosphorylation of PLC-Q1 in vitro. Given
these results, we suggest that apoptotic protease specifically
cleaves and inactivates EGFR, which plays crucial roles in anti-
apoptotic signaling, to abrogate the activation of EGFR-
dependent downstream survival signaling molecules. ß 2001
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
Besides the growth promoting properties of mitogenic sig-
naling molecules, they can also promote survival signaling by
activating anti-apoptotic responses. For example, activation
of mitochondrial protein kinase C-K results in the phosphor-
ylation of Bcl-2, and subsequently inhibits apoptosis [1]. Also,
Ras has been shown to mediate anti-apoptotic signals through
the activation of phosphatidylinositol-3-kinase (PI3K) [2]. It is
well known that Akt/PKB plays central roles in anti-apoptotic
function. Bad, a pro-apoptotic Bcl-2 family, is phosphorylated
by Akt/PKB and dissociates from Bcl-2, strengthening the
anti-apoptotic properties of Bcl-2 [3]. Recently, it has been
reported that caspase-9 is directly inactivated by Akt/PKB-
mediated phosphorylation [4]. Therefore, growth factor recep-
tor downstream signaling molecules participate in the anti-
apoptotic signals as well as mitogenic signals.
Apoptosis is a fundamental process for normal develop-
ment of multicellular organisms and is involved in the regu-
lation of the immune system, embryonic development and
maintenance of homeostasis [5]. It is well established that a
family of cellular cysteine proteases, collectively known as
caspases, act in a cascade to elicit and potentiate a number
of apoptotic responses [6]. Upon binding of Fas ligand or
tumor necrosis factor-K (TNF-K) to their cognate receptors,
caspase-8 is recruited to the death-induced signaling complex
through interaction with FADD/MORT-1 [7]. Bid is cleaved
by caspase-8, and its C-terminal domain translocates to the
mitochondria where it triggers cytochrome c release into the
cytoplasm [8]. It has been revealed that dATP together with
cytochrome c associates with Apaf-1, which is a mammalian
homolog of CED-4 [9]. Apaf-1 subsequently associates with
and activates caspase-9 resulting in the cleavage and activa-
tion of caspase-3 [10]. Caspase-3, as an executioner, cleaves
several cellular proteins that are involved in morphological
and biochemical changes that accompany apoptosis, or in
aspects of DNA damage sensing and repair.
Recently, a new paradigm has been established whereby
caspases promote apoptosis by not only activating pro-apo-
ptotic parameters but also by inactivating mitogenic or anti-
apoptotic molecules. Caspase-3 converts anti-apoptotic Bcl-2
into a Bax-like death e¡ector by cleaving the loop domain
[11]. Also, phospholipase C (PLC)-Q1 is cleaved and inacti-
vated by caspases [12]. Widmann et al. have reported that
Raf-1 and Akt/PKB are inactivated by caspase-dependent
cleavage during the apoptosis [13]. Since the survival signaling
molecules inhibit apoptosis, it is reasonable that apoptotic
proteases cleave and inactivate survival factors for the e⁄cient
progression of apoptosis.
In this study, we have demonstrated that epidermal growth
factor receptor (EGFR) is cleaved in a caspase-dependent
manner during apoptosis. Cleavage of EGFR by caspases
abrogates the activation of PLC-Q1. We suggest here, for the
¢rst time, that the gateway of survival signals such as EGFR
is a target of apoptotic proteases.
2. Materials and methods
2.1. Materials
Human epidermoid carcinoma A431 cells were purchased from
ATCC (Rockville, MD, USA). Tissue culture supplies were purchased
from Corning (Corning, NY, USA), and sera were from Hyclone
(Logan, UT, USA). Z-DEVD-fmk was purchased from Enzyme Sys-
tems Products (Dublin, CA, USA). YVAD-cmk was obtained from
Calbiochem (San Diego, CA, USA). Enhanced chemiluminescence
detection system was purchased from Amersham (Aylesbury, UK).
Monoclonal anti-EGFR antibody that speci¢cally recognizes the
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C-terminal region (amino acids (aa) 996^1022) of human EGFR was
obtained from Transduction Laboratories (Lexington, KY, USA).
Monoclonal anti-phosphotyrosine antibody (4G10) and monoclonal
anti-EGFR antibody that speci¢cally recognizes the extracellular do-
main of human EGFR were purchased from Upstate Biotechnology
(Lake Placid, NY, USA). Peroxidase-conjugated anti-mouse IgG and
anti-rabbit IgG were purchased from Kirkegaard and Perry Labora-
tories (Gaithersburg, MA, USA). Rabbit polyclonal antibody raised
to Escherichia coli expressed caspase-3 was prepared by the immuni-
zation of New Zealand white rabbits as previously described [14].
Wheat germ lectin agarose and other chemicals were obtained from
Sigma (St. Louis, MO, USA). Caspases were prepared as described
previously [15] and caspase activity was measured using speci¢c pep-
tide substrate.
2.2. Cell culture
A431 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
with 10% heat-inactivated fetal bovine serum and were maintained
at 5% CO2/95% air at 37‡C. Medium was replaced every 2 days. Cells
were maintained in 70% con£uence.
2.3. Puri¢cation of EGFR
A431 cells were washed twice with ice-cold phosphate-bu¡ered sa-
line (PBS) and then lysed with lysis bu¡er (20 mM Tris^HCl pH 7.4,
1 mM EGTA/EDTA, 1 mM Na3VO4, 2 mM sodium pyrophosphate,
10% glycerol and 1% Triton X-100). Cell lysates were applied to
wheat germ lectin agarose. Unbound proteins were washed out with
lysis bu¡er. EGFR was eluted with lysis bu¡er containing 0.3 M of
N-acetyl-D-glucosamine. The eluted EGFR fraction was applied to a
gel ¢ltration column to exchange bu¡er into cleavage assay bu¡er
(20 mM HEPES, pH 7.4, 100 mM KCl, 3 mM NaCl, 0.2 mM CaCl2
and 1 mM dithiothreitol).
2.4. Cleavage of EGFR by caspases in vitro
Cleavage of EGFR was performed by active caspases as described
previously [16]. Brie£y, reactions were initiated by the addition of
various caspases to 0.1 Wg of puri¢ed EGFR in 15 Wl of cleavage
assay bu¡er. After 1 h, the reactions were stopped by adding sodium
dodecyl sulfate (SDS) sample bu¡er. Also, the e¡ect of inhibitors such
as DEVD-fmk (10 WM) and YVAD-cmk (10 WM) on the cleavage of
EGFR by caspase-1, caspase-3 and caspase-7 was determined.
2.5. Cleavage of EGFR in A431 cells
A431 cells were incubated with TNF-K in the presence or absence
of cycloheximide (CHX) for 18 h. Both the £oating and anchoring
cells were harvested followed by washing with PBS twice. Cells were
lysed with lysis bu¡er and lysates were immunoblotted with anti-
EGFR antibody recognizing the C-terminal region of EGFR.
2.6. E¡ect of EGFR cleavage on the tyrosine phosphorylation
of PLC-Q1
Puri¢ed EGFR (0.1 Wg) was cleaved by caspase-3 (0.1 Wg) and then
reaction mixtures were incubated with DEVD-fmk (20 WM) to irre-
versibly inactivate caspase-3. 3 h after incubation with PLC-Q1 in a
kinase bu¡er (20 mM HEPES-OH pH 7.4, 25 mM MgCl2, 4 mM
MnCl2, 0.1 mM Na3VO4), phosphorylated PLC-Q1 was detected by
probing with anti-phosphotyrosine antibody. Also, cleavage of EGFR
was veri¢ed by probing with anti-EGFR antibody that recognizes the
extracellular domain of EGFR.
3. Results
3.1. Cleavage of EGFR by caspase-3 in vitro
Apoptotic caspases often cleave anti-apoptotic signaling
molecules such as Akt/PKB [13]. Among the anti-apoptotic
signaling molecules, the growth factor receptor that initiates
anti-apoptotic signaling events could be a possible target mol-
ecule of apoptotic proteases such as caspase-3 and caspase-7.
To con¢rm this idea, we incubated EGFR with active caspase-
3 in vitro. EGFR was rapidly cleaved by caspase-3 as shown
in Fig. 1. However, we could not detect the cleavage product
by an anti-EGFR antibody that speci¢cally recognizes the
C-terminal domain (aa 996^1022) of human EGFR. This re-
sult indicates that caspase-3 may cleave within the C-terminal
region of human EGFR.
3.2. Cleavage of EGFR by group II caspases
As other caspase family members have substrate speci¢city
similar to caspase-3, we investigated their ability to proteolyze
EGFR. Among those tested, group II caspases such as cas-
pase-3 and caspase-7 were most potent in the cleavage of
EGFR (Fig. 2). Interestingly, caspase-1 also potently cleaved
EGFR. However, cleavage of EGFR by other caspases such
as caspase-4, caspase-6 and caspase-8 was negligible. This re-
sult indicates that cleavage of EGFR is speci¢c for group II
caspases and caspase-1.
3.3. E¡ect of caspase inhibitors on the cleavage of EGFR
To further con¢rm the caspase-dependent cleavage of
EGFR, we determined the e¡ect of caspase inhibitors such
as DEVD-fmk (speci¢c for group II caspase) and YVAD-
cmk (speci¢c for caspase-1). Caspase-1-dependent cleavage
of EGFR was inhibited by pretreatment with both DEVD-
fmk and YVAD-cmk as shown in Fig. 3. Caspase-3-depen-
dent cleavage of EGFR was also inhibited by pretreatment
with both DEVD-fmk and YVAD-cmk. However, DEVD-
fmk was more speci¢c than YVAD-cmk in the inhibition of
caspase-7-dependent cleavage of EGFR. These results
strongly implicate that EGFR is cleaved by apoptotic cas-
pases.
3.4. Cleavage of EGFR in A431 cells
Since EGFR was cleaved by apoptotic caspases in vitro, we
next examined the cleavage of EGFR during TNF-K-induced
apoptosis in A431 cells. EGFR was not cleaved by treatment
of A431 cells with TNF-K or CHX alone. However, treatment
of A431 cells with both TNF-K and CHX potently induced
cell death (data not shown). Moreover, activation of caspase-3
and cleavage of EGFR was accompanied by co-stimulation of
A431 cells with TNF-K and CHX (Fig. 4). This result indi-
cates that EGFR is cleaved by caspases in TNF-K/CHX-in-
duced apoptosis.
Fig. 1. Proteolytic cleavage of EGFR by caspase-3. EGFR was pu-
ri¢ed as described in Section 2. 0.1 Wg of puri¢ed EGFR was incu-
bated with 0.1 Wg of active caspase-3 for the indicated times. Reac-
tions were stopped by addition of sample bu¡er, and Western blot
analysis was performed using anti-EGFR antibody that recognizes
the C-terminal region (aa 996^1022).
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3.5. Abrogation of PLC-Q1 activation by caspase-dependent
cleavage of EGFR in vitro
To dissect the meaning of caspase-dependent cleavage of
EGFR, we have examined the e¡ect of cleavage on the tyro-
sine phosphorylation of a downstream signaling molecule
such as PLC-Q1. PLC-Q1 was clearly tyrosine phosphorylated
by intact EGFR. However, tyrosine phosphorylation of PLC-
Q1 by cleaved EGFR was impaired as shown in Fig. 5. PLC-Q1
was not cleaved by caspase-3 since we inactivated caspase-3
by an irreversible inhibitor (DEVD-fmk) after cleavage of
EGFR (data not shown). This result indicates that cleavage
of EGFR by caspase results in the loss of a proper signal
transduction capability of EGFR.
4. Discussion
The occupation of growth factor receptors by their cognate
ligands induces autophosphorylation of tyrosine residues on
their receptors [17]. This stimulates recruitment of several cel-
lular proteins that are involved in proliferation, di¡erentiation
and survival [18]. Among the downstream signaling molecules,
Akt/PKB is known to play a crucial role in anti-apoptotic
function through the phosphorylation of regulatory proteins
of apoptosis [3,4]. A common end-point in the commitment of
apoptosis is the activation of executioner caspases. Inhibition
of caspases generally inhibits apoptosis. It seems to be that
di¡erent caspases di¡erentially contribute to the apoptotic
program in di¡erent cell types. Caspase-dependent cleavage
can inactivate proteins that are involved in repair mecha-
nisms, cell cycle and cellular morphology. Since many proteins
in various intracellular signaling pathways are under the con-
trol of the apoptotic response, we were interested in determin-
ing whether signaling proteins could be cleaved by apoptotic
caspases.
We have found that EGFR is one such signaling protein.
EGFR was preferentially cleaved by group II caspases, which
play a crucial role in the execution phase of apoptosis [19]. It
has been reported that pretreatment of cells with a protein
synthesis inhibitor such as CHX is required for TNF-K-in-
duced activation of caspases and apoptosis [20]. Cleavage of
EGFR by TNF-K treatment was induced in the presence of
protein synthesis inhibitor. Therefore, cleavage of EGFR
might be induced by apoptotic proteases. Also, our result
showed that activation of caspase-3 correlated with the cleav-
age of EGFR.
Caspases cleave the consensus sequence (DXXD) of their
substrate proteins [19]. Recently it has been reported that the
P1 position should be followed by a small amino acid such as
alanine or glycine to be a good substrate of caspases [21].
EGFR contains several consensus sequences such as
DEED1006, DMDD1009 and DYYD1012 (Fig. 6). The P1 posi-
tion of all these candidate sites is followed by a small amino
Fig. 2. Cleavage of EGFR by group II caspases. 0.1 Wg of puri¢ed
EGFR was incubated with caspase-1, -4, -6, -3, -7, -8 or -2 for 30
min. Reactions were stopped by addition of sample bu¡er, and
Western blot analysis was performed using anti-EGFR antibody
that recognizes the C-terminal region of EGFR.
Fig. 3. E¡ect of caspase inhibitors on the in vitro cleavage of
EGFR. Caspase-1, caspase-3 and caspase-7 were incubated with
EGFR in the absence or presence of either DEVD-fmk (10 WM) or
YVAD-cmk (10 WM) for 30 min. Reactions were stopped and
EGFR was probed with anti EGFR antibody that recognizes the
C-terminal region of EGFR.
Fig. 4. Cleavage of EGFR during TNF-K-induced apoptosis. A431
cells (1U106) were stimulated with TNF-K in the presence or ab-
sence of CHX and medium containing 1% fetal bovine serum for 18
h. Floating and anchoring cells were harvested and washed twice
with PBS. Lysates were subjected to SDS^PAGE and probed with
either anti-EGFR antibody (upper panel) or anti-caspase-3 antibody
(lower panel).
Fig. 5. E¡ect of cleavage on the activation of PLC-Q1. 1 Wg of
EGFR was incubated with active caspase-3. After 1 h, DEVD-fmk
was added to the reaction mixture. Proteolytic cleavage of EGFR
was probed with anti-EGFR antibody that recognizes the extracellu-
lar domain of EGFR (A). Each intact and cleaved EGFR was incu-
bated with puri¢ed PLC-Q1 (0.1 Wg) for 2 h as described in Section
2. Tyrosine phosphorylation of PLC-Q1 was detected by immuno-
blotting with anti-phosphotyrosine monoclonal antibody (B).
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acid. Since we have detected a 160 kDa cleavage product with
an anti-EGFR antibody that recognizes the extracellular do-
main of EGFR, it is reasonable that apoptotic caspases may
cleave the sequence around aa 1006^1012. However, we could
not detect other small cleavage products with an antibody
that recognizes the C-terminal region (aa 996^1022). It has
been reported that the major phosphorylation site of EGFR
is Tyr1197 [22]. Because anti-pTyr antibody could not detect
any cleavage product of EGFR, caspases may cleave a 22 kDa
cleavage product into a smaller fragment, which is undetect-
able by Western blot analysis. Therefore, DNPD1171 might be
another possible cleavage site of caspases though the P1 posi-
tion is followed by a bulky amino acid. Collectively, EGFR
may be cleaved at multiple sites of the C-terminal region that
acts as a docking site for signaling molecules. The mutational
studies are required for the identi¢cation of cleavage sites.
Many signaling molecules are activated by EGFR through
its tyrosine phosphorylation at speci¢c sites. It has been re-
ported that PLC-Q1 is activated by EGFR through tyrosine
phosphorylation at Tyr771, Tyr783 and Tyr1254 [23]. Especially,
tyrosine phosphorylation at Tyr783 takes precedence over all
other sites for the activation of PLC-Q1. Based on our results,
EGFR cleavage by caspase-3 results in defective tyrosine
phosphorylation of PLC-Q1. Since candidate cleavage sites re-
side in the docking site of signaling molecules including PLC-
Q1, cleavage of EGFR by caspase-3 may a¡ect the recruiting
of signaling molecules to EGFR. Also, it has been reported
that the C-terminal region deleted mutant of EGFR is defec-
tive in the recruitment of PLC-Q1 and GAP [24]. Therefore,
activation of apoptotic caspases leads to the inactivation of a
signaling complex between EGFR and PLC-Q1.
Stimulation of the growth factor receptor results in the
suppression of apoptosis in various cells [25]. Many signaling
molecules such as PI3K, PLC-Q1, Ras, ERK and Akt are
involved in the suppressive mechanism of apoptosis. Also,
there are other anti-apoptotic proteins such as Bcl-2 and
Bcl-XL that control the activation of caspases. All of these
proteins are involved in the inhibition of apoptosis. It is well
established that apoptotic caspases speci¢cally cleave signaling
molecules playing negative roles in apoptosis. Since activation
of anti-apoptotic signaling molecules is initiated by stimula-
tion of the growth factor receptor, inactivation of the growth
factor receptor itself by apoptotic caspases may be the most
e⁄cient way to propagate death signals. However, we could
not exclude the possibility that di¡erent sets of proteins
should be cleaved at various stages of the apoptotic responses
in a temporally ordered manner to cause cell death. The full
understanding of the interplay between EGFR and caspases
and their signaling mechanisms still requires a lot of study.
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